This company listing is no longer active
U4W0 Stock Overview
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Quotient Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.12 |
| 52 Week High | €15.36 |
| 52 Week Low | €0.018 |
| Beta | 1.36 |
| 1 Month Change | 313.79% |
| 3 Month Change | 196.30% |
| 1 Year Change | -99.22% |
| 3 Year Change | -99.96% |
| 5 Year Change | -99.96% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| U4W0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.0% | -1.2% |
| 1Y | -99.2% | -3.7% | 1.2% |
Return vs Industry: U4W0 underperformed the German Medical Equipment industry which returned 9.3% over the past year.
Return vs Market: U4W0 underperformed the German Market which returned 1.9% over the past year.
Price Volatility
| U4W0 volatility | |
|---|---|
| U4W0 Average Weekly Movement | 95.4% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: U4W0's share price has been volatile over the past 3 months.
Volatility Over Time: U4W0's weekly volatility has increased from 63% to 95% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 432 | Manuel Mendez | www.quotientbd.com |
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.
Quotient Limited Fundamentals Summary
| U4W0 fundamental statistics | |
|---|---|
| Market cap | €2.53m |
| Earnings (TTM) | -€112.90m |
| Revenue (TTM) | €34.05m |
0.1x
P/S Ratio0.0x
P/E RatioIs U4W0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| U4W0 income statement (TTM) | |
|---|---|
| Revenue | US$37.41m |
| Cost of Revenue | US$37.13m |
| Gross Profit | US$279.00k |
| Other Expenses | US$124.31m |
| Earnings | -US$124.03m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.89 |
| Gross Margin | 0.75% |
| Net Profit Margin | -331.54% |
| Debt/Equity Ratio | -126.2% |
How did U4W0 perform over the long term?
See historical performance and comparison